Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company’s revenue at about ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... In 2021, Xyrem generated over $1.8 billion in revenue for Jazz. Jazz has denied the allegations, stating that the judge’s order ...

U.S sterile injectables market is estimated to be valued at US$ 131.8 billion in 2022 and expected to exhibit a CAGR of 9.3% over the forecast period 2022-2030 ...

European stocks closed on a strong note on Thursday with investors cheering the Federal Reserve's decision to cut interest rates by ...

The pan European Stoxx 600 closed with a gain of 1.38 per cent. The UK's FTSE 100 gained 0.91 per cent, Germany's DAX climbed 1.55 per cent, and France's CAC 40 ended up 2.29 per cent, while ...

BROKER RATING CHANGES Berenberg raises Hikma Pharmaceuticals to 'buy' (hold ... % to USD544 million from USD585 million a year prior. Revenue, however, was up 2% to USD2.75 billion from USD2.70 ...

Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...